441 related articles for article (PubMed ID: 10990271)
1. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis.
Cross EW; Park S; Perlin DS
Microb Drug Resist; 2000; 6(2):155-61. PubMed ID: 10990271
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals.
Mathema B; Cross E; Dun E; Park S; Bedell J; Slade B; Williams M; Riley L; Chaturvedi V; Perlin DS
Clin Infect Dis; 2001 Sep; 33(5):E23-7. PubMed ID: 11477529
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis.
Nagashima M; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 Feb; 22(2):124-6. PubMed ID: 26627336
[TBL] [Abstract][Full Text] [Related]
4. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
[TBL] [Abstract][Full Text] [Related]
5. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.
Danby CS; Boikov D; Rautemaa-Richardson R; Sobel JD
Antimicrob Agents Chemother; 2012 Mar; 56(3):1403-6. PubMed ID: 22232293
[TBL] [Abstract][Full Text] [Related]
6. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
Wong-Beringera A; Hindler J; Brankovic L; Muehlbauer L; Steele-Moore L
Diagn Microbiol Infect Dis; 2001 Jan; 39(1):25-31. PubMed ID: 11173188
[TBL] [Abstract][Full Text] [Related]
7. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata.
Defontaine A; Bouchara JP; Declerk P; Planchenault C; Chabasse D; Hallet JN
J Med Microbiol; 1999 Jul; 48(7):663-670. PubMed ID: 10403417
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activity between Echinophora platyloba DC ethanolic extract and azole drugs against clinical isolates of Candida albicans from women suffering chronic recurrent vaginitis.
Avijgan M; Mahboubi M; Moheb Nasab M; Ahmadi Nia E; Yousefi H
J Mycol Med; 2014 Jun; 24(2):112-6. PubMed ID: 24746726
[TBL] [Abstract][Full Text] [Related]
9. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
Adjapong G; Hale M; Garrill A
Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
[TBL] [Abstract][Full Text] [Related]
10. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.
Lynch ME; Sobel JD; Fidel PL
J Med Vet Mycol; 1996; 34(5):337-9. PubMed ID: 8912167
[TBL] [Abstract][Full Text] [Related]
11. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic
Kane A; Dinh H; Campbell L; Cain AK; Hibbs D; Carter D
Microbiol Spectr; 2024 Jun; 12(6):e0012124. PubMed ID: 38695556
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.
Hacioglu M; Guzel CB; Savage PB; Tan ASB
Med Mycol; 2019 Apr; 57(3):291-299. PubMed ID: 29846682
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents.
Choukri F; Benderdouche M; Sednaoui P
J Mycol Med; 2014 Dec; 24(4):303-7. PubMed ID: 25442913
[TBL] [Abstract][Full Text] [Related]
15. [Azole resistance in Candida albicans].
Perea S
Rev Esp Quimioter; 2000 Sep; 13(3):314-7. PubMed ID: 11086283
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003.
da Matta DA; de Almeida LP; Machado AM; Azevedo AC; Kusano EJ; Travassos NF; Salomão R; Colombo AL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):399-404. PubMed ID: 17240110
[TBL] [Abstract][Full Text] [Related]
17. Determining Susceptibility in
Sobel JD; Akins R
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0236621. PubMed ID: 35604210
[TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.
Richter SS; Galask RP; Messer SA; Hollis RJ; Diekema DJ; Pfaller MA
J Clin Microbiol; 2005 May; 43(5):2155-62. PubMed ID: 15872235
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.
Lynch ME; Sobel JD
J Med Vet Mycol; 1994; 32(4):267-74. PubMed ID: 7983571
[TBL] [Abstract][Full Text] [Related]
20. In vivo activity of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida species.
Damke E; Tsuzuki JK; Cortez DA; Ferreira IC; Bertoni TA; Batista MR; Donati L; Svidzinski TI; Consolaro ME
BMC Complement Altern Med; 2011 May; 11():35. PubMed ID: 21542936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
